杭州又一家AI合成生物企业完成融资

Core Viewpoint - AiBio (Hangzhou) Biotechnology Co., Ltd. has completed a Pre-A round financing of several tens of millions, positioning itself as a leading provider of bio-manufacturing technology services and products, integrating biological engineering and artificial intelligence [2]. Group 1: Core Technology Platform - The AIxBio intelligent fermentation platform integrates cutting-edge technologies such as enzyme engineering, gene editing, and metabolic network modification, allowing for the simulation of complex fermentation environments and prediction of bioreactor fluid behavior, addressing the common "scale-up effect" issue in synthetic biology [3]. Group 2: Product Pipeline - The product pipeline focuses on the beauty and health sector, particularly the development of high-activity peptide raw materials: - The "001 series" peptide products are developed in collaboration with Huisi Le, utilizing AI technology for sequence optimization and expression system construction to achieve efficient and low-cost production [4]. - The company is developing a series of bioactive peptide molecules for high-end skincare products and functional foods based on its gene editing and metabolic network modification platform [4]. - AiBio also offers customized bio-manufacturing services, providing comprehensive technical solutions from strain modification to process scaling for partners [4].